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SUMMARY
Host defense depends on orchestrated cell migration
guided by chemokines that elicit selective but biased
signaling pathways to control chemotaxis. Here, we
showed that different inflammatory stimuli provoked
oligomerization of the chemokine receptor CCR7,
enabling human dendritic cells and T cell subpopula-
tions to process guidance cues not only through
classical G protein-dependent signaling but also by
integrating an oligomer-dependent Src kinase sig-
naling pathway. Efficient CCR7-driven migration de-
pends on a hydrophobic oligomerization interface
near the conserved NPXXY motif of G protein-
coupled receptors as shown by mutagenesis screen
and a CCR7-SNP demonstrating super-oligomer
characteristics leading to enhanced Src activity and
superior chemotaxis. Furthermore, Src phosphory-
lates oligomeric CCR7, thereby creating a docking
site for SH2-domain-bearing signaling molecules.
Finally, we identified CCL21-biased signaling that
involved the phosphatase SHP2 to control efficient
cell migration. Collectively, our data showed that
CCR7 oligomers serve as molecular hubs regulating
distinct signaling pathways.
INTRODUCTION
Acute inflammation is the host’s major reaction to invading path-
ogens and the coordinated recruitment of cells to distinct sites is
a hallmark of the immune system to eliminate the intruder (Medz-
hitov, 2010). Locally residing dendritic cells (DCs) sense the
invading pathogen and transport antigens to the draining lymph
nodes to launch a pathogen-specific adaptive immune response
involvingTandBcells (Joffre et al., 2009).Orchestratedmigration
of antigen-loadedDCs and T cells to secondary lymphoid organs
relies on the chemokine receptor CCR7 and its two ligands,
CCL19 and CCL21; alterations within the CCR7-CCL19/CCL21
axis severely impair both immunity and tolerance (Comerford
et al., 2013; Fo¨rster et al., 2008). Of note, DCs encountering infec-
tious or inflammatory insults undergo maturation and induce
CCR7 expression. Lymphatic endothelial cells in the skin
constitutively produce CCL21, forming a chemokine gradient
(Weber et al., 2013). This haptotactic chemokine gradient guides
CCR7-expressing DCs from the perilymphatic interstitium into
the lymphatic capillaries. DCs are then transported by the lymph
flow into the subcapsular sinus of the draining lymph node
from where DCs again actively migrate along a CCL21 gradient
established between the T zone and the subcapsular sinus
(Ulvmar et al., 2014). Circulating CCR7-expressing T cells enter
lymph nodes through high endothelial venules, where presented
CCL21 facilitates integrin activation and entrance. Subsequently,
CCR7 signaling contributes to intranodal motility of T cells and
their encounter with antigen-bearing DCs (Braun et al., 2011).
Given the importance of CCR7 and its ligands in immunity and
tolerance, tightly regulated production of both receptor and li-
gands have been reported to ensure appropriate responses
(Comerford et al., 2013). In addition, several post-translational
mechanisms have been observed to regulate cell responses to
CCL19 and CCL21. Most prominently, inflammatory signals
(MartIn-Fontecha et al., 2003) and the inflammatory lipid medi-
ator prostaglandin (PG)E2 (Kabashima et al., 2003; Legler et al.,
2006) were identified as key factors for fast and efficient DC
migration and homing to lymph nodes. Despite this key function,
the underpinning molecular mechanism is unknown.
Chemokine receptors belong to the class A of G protein-
coupled receptors (GPCRs) and utilize heterotrimeric G proteins
to initiate signal transduction. Most chemokine-driven signaling
events rely on pertussis toxin (PTx)-sensitive Gai protein
coupling, including those responsible for lymph node homing
(Thelen and Stein, 2008). However, recent discoveries point to
alternative but poorly defined signaling possibilities of chemo-
kine receptors. Most conspicuously, effector T cells—in contrast
to naive T cells—were shown to exploit Src kinase activity to
bypass chemokine-mediated Gai protein signaling to arrest
and crawl on inflamed vessels (Shulman et al., 2012). The rela-
tively new concept by which a GPCR ligand can preferentially
activate one of several available signaling pathways is termed
biased signaling (Rajagopal et al., 2010; Steen et al., 2014).
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Notably, selective signaling by CCL19 and CCL21 have been
identified downstream of CCR7. CCL21, through its unique,
highly charged C-terminal extension, binds to glycosaminogly-
cans, becomes immobilized, and drives integrin-mediated
adhesion and migration (Schumann et al., 2010). Conversely,
only CCL19 induces robust CCR7 phosphorylation on Ser/Thr
residues (Kohout et al., 2004) by G protein-coupled receptor ki-
nase 3 (Zidar et al., 2009), resulting in b-arrestin recruitment and
CCR7 internalization (Otero et al., 2006). How the two ligands
can trigger distinct CCR7 signaling pathways remains poorly
understood.
The complexity of chemokine signaling is further enlarged by
receptor homo- and hetero-oligomerization. Both allosteric inhi-
bition and synergistic activation of chemokine receptor hetero-
oligomerization have been reported for various receptor pairs
(Stephens and Handel, 2013). For CCR7, it is interesting to
note that HIV-1 was shown to evoke CXCR4 signaling promoting
CCR7-mediated CD4+ T cell responses through an unknown
mechanism that possibly involves oligomerization (Hayasaka
et al., 2015). Recent structural discoveries derived from non-
chemokine receptors revealed that in a GPCR dimer, only one
receptor is able to interact with the G protein and that the G pro-
tein-free GPCR is capable to allosterically modulate the signaling
outcome of the receptor dimer (Han et al., 2009; Huang et al.,
2013). This might provide a new twist for understanding func-
tional consequences of chemokine receptor oligomerization.
Inspired by these findings, we posed the question as to whether
environmental conditions, such as inflammatory stimuli, are able
to modulate the oligomerization state of CCR7, enabling alterna-
tive signaling that accounts for efficient T cell and DC migration.
Here, we identified that an inflammatory signal mediated by
PGE2 provoked CCR7 oligomerization on human monocyte-
derived (Mo)DCs, resulting in efficient migration. The same sig-
nals were found to downregulate the cholesterol metabolism in
MoDCs. Cells treated with cholesterol-lowering drugs enhanced
CCR7 oligomerization, so we proposed that PGE2 lowers
cholesterol levels to promote CCR7 oligomerization and efficient
DC migration. Moreover, we identified CCR7 oligomers on DCs
proximal to lymphatic vessels in human skin. In addition, we
showed that CCR7 oligomers functioned to integrate G pro-
tein-dependent and Src kinase-dependent signaling at the
GPCR oligomer. By using directed evolutionary screening, we
developed the concept that efficient CCR7-driven cell migration
depended on receptor oligomerization. This concept was sub-
stantiated by the identification of a CCR7-SNP owning super-
oligomer characteristics manifested by enhanced Src activity
and superior chemotaxis. Furthermore, we discovered that Src
tyrosine phosphorylated CCR7 and demonstrated that this
phosphorylation site served as docking site for SH2-domain-
bearing signaling molecules. Finally, we identified a CCL21-
biased signaling pathway involving the phosphatase SHP2 that
controlled efficient cell migration.
RESULTS
PGE2 Induces CCR7 Oligomerization and Promotes
Efficient DC Migration
DCs reside as sentinels in the skin and mucosal tissue and sam-
ple the periphery for invading pathogens. After activation by in-
fectious or inflammatory stimuli, DCsmigrate into draining lymph
nodes in a CCR7-dependent manner where they present periph-
erally acquired antigens to T cells, thereby launching an adaptive
immune response. Notably, initiation of skin immune responses
and DC homing is severely impaired in mice lacking the PGE2 re-
ceptor EP4 (Kabashima et al., 2003). Similarly, human ex vivo
DCs and MoDCs efficiently migrated in response to CCR7 li-
gands only if DCs were exposed to PGE2 (Figure 1A; Legler
et al., 2006). This pro-migratory DC phenotype could not be ex-
plained by PGE2-mediated upregulation of CCR7 expression
(Figure 1B) or by altered classical chemokine receptor signaling
(Scandella et al., 2004). BecauseGPCR oligomerization is postu-
lated to facilitate alternative signaling (Han et al., 2009), we
thought to investigate whether PGE2 triggering might modulate
the oligomerization state of CCR7 and thereby facilitates efficient
DC migration. To this end, we measured protein-protein interac-
tion of endogenous CCR7 molecules in situ by proximity ligation
assay (PLA). Indeed, profound CCR7 oligomerization, as mani-
fested by red fluorescent dots, was most prominently found in
human MoDCs matured in the presence of PGE2 (Figure 1C).
CCR7 oligomerization was also observed on activated, CD3/
CD28-expanded human effector and central memory T cells
(Figure S1A). CCR7 oligomers were also detected on freshly iso-
lated PBLs and naive T cells but to a much lower amount (Fig-
ure S1A), suggesting that activation signals in general promoted
Figure 1. Inflammatory Signals Induce CCR7 Oligomerization and Cellular Cholesterol Depletion and Promote DC Migration
(A) Human MoDCs matured in the presence or absence of PGE2 were subjected to 2D Transwell migration assays toward CCL19 and CCL21.
(B) Surface expression of CCR7 on human MoDCs matured in the presence (dashed black lines tinted blue) or absence (black line) of PGE2 measured by flow
cytometry. Isotype control in tinted light gray.
(C) Micrographs of DIC and confocal 3D reconstruction showing CCR7 oligomerization measured by PLA using anti-CCR7 mAb (clone 6B3) on human MoDCs
matured with cytokine cocktail (CC) in the presence or absence of PGE2.
(D–F) Micrographs of CCR7 oligomers determined by PLA using anti-CCR7 mAb (clone 6B3) at LYVE-1+ lymph vessels (D) or using anti-CCR7 antibody (clone
mab197) on CD11c+ and CD3+ cells (F) in snap frozen human skin sections (thickness: 8 mm). Squares indicate magnification for i (middle) and ii (bottom).
(G) Micrographs of DIC and confocal 3D reconstruction of CCR7 oligomers on humanMoDCs matured with CC and PGE2 in the absence (untreated) or presence
of Mevastatin or Pravastatin. In addition, mature MoDCs were treated with MbCD or cholesterol oxidase for 2 hr.
(H) Quantification of CCR7 oligomerization upon cholesterol deprivation in MoDCs as shown in (G) from at least 190 cells from six individual experiments.
(I) Structural model of CCR7 and cholesterol (in red) at a putative CCR7 dimer interface based on solved crystal structures (PDB: 2RH1, 3SN6).
(J) Quantitative real-time PCR analysis of genes in human MoDCs matured in the presence or absence of PGE2. Fold change compared to 2^(D(Ct)) values of
immature MoDCs is depicted as a color coded heat-map.
(K) Changes in the expression levels of selected genes depicted in (J) in MoDCs upon maturation and PGE2 stimulation.
Data are from four to six independent experiments of individual donors (A–H, J–K). Error bars represent SD; ANOVA with Tukey (A, K) or Dunnett (H) post test.
Scale bars represent 10 mm. See also Figure S1.
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Figure 2. CCR7 Forms Oligomers in Steady State, Is Ligand and Cholesterol Sensitive, and Involves Two Interfaces
(A) Confocal image of CCR7 homo-oligomerization and FRET efficiency determined by donor recovery after acceptor photo-bleaching in HEK293 cell trans-
fectants.
(B and C) Quantification of FRET efficiency in HEK293 cells expressing CCR7-YFP and indicated constructs. Cells were treated or not with 5 mM MbCD or
cholesterol pre-saturated MbCD (C).
(D) Confocal image of CCR7 homo-oligomerization determined by BiFC.
(E) Quantification of CCR7 oligomerization measured by BiFC and flow cytometry in HEK293 transfectants upon stimulation with 0.5 mg/ml chemokine.
(F) CCR7 oligomerization determined by chemical crosslinking of endogenous cysteines in non-reducing SDS-PAGE in HEK293 transfectants treated or not with
MbCD or cholesterol-pre-saturated MbCD.
(G) CCR7 oligomerization deciphered by crosslinking cysteine residues introduced at indicated positions adjacent to the TM in non-reducing SDS-PAGE.
(legend continued on next page)
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CCR7 oligomerization. In line with our observations on MoDCs,
CD45RO+ human T cells are reported to migrate more efficiently
in response to CCL21 than CD45RA+ T cells (Mayya et al., 2015).
In our experimental setup, activated T cells migrate readily but
less efficiently in response to CCR7 ligands (Schaeuble et al.,
2011), but were more resistant to G protein inhibition by PTx
(Figure S1B).
To explore CCR7 oligomerization in vivo, wemeasured CCR7-
CCR7 interaction by PLA in human skin biopsies. CCR7 oligo-
merization was mainly found in proximity to LYVE-1-positive
lymph vessels (Figures 1Di and 1Ei), but hardly in neighboring tis-
sue distal from lymphatics (Figures 1Dii and 1Eii). Subsequent
co-staining experiments revealed that cells possessing CCR7
oligomers were CD11c or CD3 positive (Figure 1F). Thus, we
identified CCR7 oligomerization not only on cells that migrated
into human skin lymphatics, but also on PGE2-exposed MoDCs
that readily migrated in response to CCR7 ligands, suggesting a
role of CCR7 oligomerization in efficient cell migration.
PGE2 Regulates Cellular Cholesterol Levels to Facilitate
CCR7 Oligomerization on DCs
Because DC homing is impaired in inflammatory disease models
where cholesterol accumulates in the skin (Angeli et al., 2004)
and because cholesterol intercalation between two b2-ARmole-
cules is shown to modulate the GPCR dimer interface (Figure 1I;
Cherezov et al., 2007; Prasanna et al., 2014), we determined
CCR7 oligomerization in MoDCs treated with low doses of
cholesterol-lowering drugs (Mevastatin and Pravastatin to inhibit
cholesterol biosynthesis; methyl-b-cyclodextrin [MbCD] to
sequester plasma membrane cholesterol) and with cholesterol
oxidase. Lowering cholesterol levels in MoDCs significantly
increased CCR7 oligomerization (Figures 1G and 1H). Based
on these observations, we examined whether DC maturation
modulated the expression of enzymes for cholesterol biosyn-
thesis. We found that MoDC maturation was accompanied by
downregulation of major constituents of the cholesterol biosyn-
thesis, metabolism, and transport pathways, whereas the
cholesterol hydrolase CYP7B1 was significantly upregulated
(Figures 1J and 1K). Notably, gene regulation of key enzymes
controlling cellular cholesterol was significantly more pro-
nounced in PGE2-matured MoDCs (Figure 1K), indicating that
PGE2 enabled CCR7 oligomerization by lowering cellular
cholesterol.
CCR7 Forms Homo-mers in Steady-State and
Oligomerization Is Enhanced by Cholesterol
Sequestration and Ligand Binding
Given our identification of CCR7 oligomerization on MoDCs and
cells migrated into skin lymphatics, we were prompted to deci-
pher the underlying mechanism. Therefore, we first conducted
Fo¨rster resonance energy transfer (FRET) experiments by donor
recovery after acceptor photo-bleaching between two CCR7
molecules. A marked FRET signal was measured between
CCR7-CFP and CCR7-YFP in steady-state (Figures 2A, 2B,
and S2A). The FRET signal was enhanced upon cholesterol
sequestration (Figure 2C). Next, we used the split-YFP-based
bimolecular fluorescence complementation (BiFC) approach
(Nyfeler et al., 2005) to corroborate oligomerization, where two
non-fluorescent YFP fragments were fused to two distinct
CCR7molecules. Upon CCR7 dimerization, the two non-fluores-
cent halves of YFP1 and YFP2 reconstituted to form a native YFP
that emitted its fluorescent signal upon excitation (Figure S2B).
Under steady-state conditions, CCR7 molecules were ex-
pressed as homo-dimers (Figure 2D). CCR7 dimerization was
not due to molecular crowding and coincidental collision at the
plasmamembrane as shown by the fact that no hetero-dimeriza-
tion was detected with increasing amounts of TMEM16a (Fig-
ure S2A) or by co-expressing the GABA transporter GAT1 (Fig-
ures 2E and S2C). CCR7 dimerization further increased upon
CCL19 and CCL21 stimulation as assessed by BiFC and FRET
(Figures 2E and S2D). Notably, complemented CCR7-YFP di-
mers were readily observed in endosomal vesicles upon
CCL19 stimulation, demonstrating normal trafficking of the
CCR7 oligomer (Figure 2D). Using chemical crosslinking of
endogenous cysteines within CCR7 allowing us to distinguish a
monomer from a crosslinked oligomer in non-reducing SDS-
PAGE, we found that cholesterol sequestration by MbCD
enhanced CCR7 dimerization as indicated by the high-molecu-
lar-weight band (Figure 2F). No molecular weight shift was
observed upon treatment with cholesterol-saturated MbCD.
Notably, cholesterol sequestration by MbCD not only facilitated
CCR7 oligomerization but also enhanced CCR7-driven cell
migration (Figure S2E). These findings demonstrated specific
CCR7 oligomerization not only in the steady-state but also
upon ligand stimulation and upon cholesterol sequestration.
Determining CCR7 Oligomerization Interfaces
To gain insight into the function of the CCR7 oligomer, we first
aimed to identify the interfaces of the CCR7 oligomer by exploit-
ing cysteine crosslinking. Therefore, we introduced individual
cysteine residues at the beginning and end of every transmem-
brane domain (TM) of CCR7. The cysteine residues can be chem-
ically crosslinked in case the TM domains are adjacent within a
symmetric oligomer. We found that the introduced cysteines at
the cytoplasmic end of TM3 and TM7 as well as the extracellular
part of TM1, TM2, TM3, and TM7 could be crosslinked (Fig-
ure 2G). To develop testable hypotheses on the function of
CCR7 oligomerization, we fitted the amino acid structures of
CCR7 into solved crystal structures of oligomeric GPCRs by
considering insights from the crosslinking experiment. As
templates to model oligomeric CCR7, we used the oligomeric
structures of b2-AR (Figure 2H), CXCR4/m-opioid-receptor (Fig-
ure S2F), and CCR5 (Figure S2G). All three CCR7 models pre-
dicted a first common oligomer interface comprising the end of
TM7 and helix (HL)8. In contrast, the second oligomer interface
differed substantially between models. Whereas the second
(H) Structure model of oligomeric CCR7 based on b1-AR (PDB: 4GPO). Surfaces involved in the oligomer interfaces are in blue. Conserved GPCR
domains are shown in green (DRY motif) and red (NPXXY motif). Side view, as well as views from the extracellular and the cytoplasmic surface of the oligomers,
are shown.
Data represent three (D) or four independent experiments. Error bars represent SEM (B, C) or SD (E). ANOVA with Tukey post test. See also Figure S2.
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oligomer interface of the b2-AR- and the CCR5-based CCR7
model included the tip of TM1, TM2, and intracellular loop (ICL)
2 (Figures 2H and S2G), the second oligomer interface of the
CXCR4-based CCR7model included TM5 and TM6 (Figure S2F).
To test the three CCR7 models, we generated CCR7 mutants
where twokey residues in either ICL2,HL8, or TM5were replaced
by alanines and expressed them in our split-YFP BiFC system.
Because the alanine mutation in TM5 was expressed at the
plasma membrane but did not influence CCR7 oligomerization
(Figure S2H), we excluded theCXCR4-based CCR7 oligomeriza-
tion model. In contrast, mutations in ICL2 and HL8 profoundly
diminished CCR7 oligomerization but also prevented its surface
expression (Figure S2H). The b2-AR- and CCR5-based CCR7
models differed primarily in the symmetry of higher oligomers.
In the b2-AR-based CCR7 model, the oligomers were arranged
as head-to-head and tail-to-tail tandems, whereas in the
CCR5-based model, the oligomers were arranged in a stacked
head-to-tail conformation. Becausewe could not further discrim-
inate the two remaining models experimentally, we were consid-
ering both CCR7 oligomer models for further analysis. Nonethe-
less, we corroboratedCCR7 oligomerization by identifying CCR7
oligomerization interfaces, one involving TM7 and HL8 and the
other one comprising ICL2, TM1, and TM2, and we provided
CCR7 oligomer models that could be tested functionally.
The Hydrophobic Interaction Surface Proximate to the
NPXXY Motif in TM7 Is Key for CCR7 Oligomerization
To determine the functional consequence of CCR7 oligomeriza-
tion, we next aimed to identify CCR7mutants that were impaired
in forming oligomers but remained readily expressed at the cell
surface. To achieve this, we established and performed a
directed evolutionary screen (Figure 3A) by which we cloned a li-
brary of CCR7 mutants randomly modified in ICL2 and TM7/HL8
into our split YFP1 vector. The library was then transfected into
cells expressing wild-type CCR7-YFP2. Cells expressing CCR7
mutants that were no longer capable of reconstituting YFP due
to the inability to form oligomers were sorted and the transfected
plasmids were recovered, amplified, diversified by random
mutagenesis, and re-transfected (Figure 3A). Then, we sorted
cells that expressed CCR7 mutants at the plasma membrane
but were negative for YFP complementation (Figure 3A). By
sequencing the recovered plasmids, we identified distinct
CCR7mutants that all harbored single-point mutations in vicinity
of the NPXXY motif of TM7 (Figures 3C and S3C). We performed
plasmid titration transfection experiments and determined the
oligomerization state of the CCR7 mutants using BiFC. The
CCR7 mutants A315G (Figure 3B) and L325S (Figure S3A)
showed profoundly reduced oligomerization compared to wild-
type CCR7. Generating a CCR7 A315G,L325S double mutant
further decreased the ability to oligomerize (Figure 3B). Notably,
the identified oligomerization-defective mutants possessed a
reduced hydrophobic interaction surface in the first oligomer
interface of our oligomeric CCR7 models.
Generation and Identification of a Natural CCR7 Super-
oligomerizer
Based on our finding that the hydrophobic interaction surface in
the oligomer interfacewas key in determining the oligomerization
state, we hypothesized that enlarging the hydrophobic surface
near the NPXXY motif might further increase CCR7 oligomeriza-
tion. Intriguingly, doubling the hydrophobic interaction surface
by replacing A315 to valine created a CCR7 mutant behaving
as super-oligomerizer (Figure 3B). Next, we wondered whether
any natural SNP variant of CCR7 would follow this rule.
By searching the public SNP database of NCBI (http://www.
ncbi.nlm.nih.gov/projects/SNP), we indeed identified a natural
G to A nucleotide polymorphism at position 1024 (SNP
rs200720683), revealing a V317I substitution, occurring with a
heterozygosity of 0.002, which exactly followed our rule. We
cloned this CCR7 V317I SNP and demonstrated its super-oligo-
merization property by BiFC (Figure 3B). Taken together, we
discovered that the hydrophobic surface of the oligomer inter-
face build between TM7 and HL8 determined the oligomerization
state of CCR7. Moreover, we identified CCR7 mutants that were
impaired in forming oligomers and discovered a natural CCR7
SNP acting as super-oligomerizer.
Oligomerization State of CCR7 Determines Cell
Migration Efficiency
Next, we generated immune cell lines expressing the CCR7 olig-
omermutants to determine theirmigratory capacity. Significantly
fewer cells expressing CCR7mutants with reduced oligomeriza-
tion state migrated in response to CCL19 and CCL21 in 2D
Transwell assays (Figure 3D) and through 3D collagen I matrix
(Figure S3B) as compared to cells expressing wild-type CCR7.
In contrast, two to three times more cells expressing the su-
per-oligomerizing CCR7 V317I SNP migrated toward CCL19
and CCL21 (Figures 3D and S3B). Hence, our data revealed
that enhanced CCR7 oligomerization correlated with the capac-
ity to promote efficient cell migration.
Next, we sought to design peptides mimicking the oligomer
interfaces that ideally would intercalate between two CCR7
molecules, thereby interfering with receptor oligomerization. To
strengthen the interaction of the peptides with the oligomer inter-
face, we also designed peptides where amino acids were
substituted to allow additional ionic interactions. Based on our
CCR7 oligomerization models, we designed five different pep-
tide candidates (Figures 3C and S3C). Incubation of cells ex-
pressing CCR7 split-YFP constructs with the peptides reduced
CCR7 oligomerization (Figure S3D). Moreover, primary human
T cells incubated with the intercalating peptides, but not with
scrambled peptides, showed hampered cell migration in
response to CCR7 ligands (Figure 3E) without downregulating
CCR7 surface expression (Figure S3E).
Chemokine binding (Figure S3F) and G protein activation (Fig-
ures S3G and S3H) were similar for wild-type CCR7 and their
oligomerization mutants, so it is tempting to speculate that
CCR7 oligomerization promoted efficient cell migration through
an additional signaling pathway aside from Gai activation.
CCR7 Oligomer Serves as Signaling Scaffold for Src
Because effector T cell crawling on inflamed vessels relies on
Src activity (Shulman et al., 2012) and because Src kinases
modulate CCR7-driven T cell migration (Schaeuble et al.,
2011), we investigated whether Src kinase interacted with the
CCR7 oligomer. Src interacted with CCR7 in the steady
state (Figures 4A and S4A). Src interaction with the CCR7 mu-
tants with reduced oligomerization capacity (L325S, A315G,
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Figure 3. Cell Migration Efficiency Is Determined by the Oligomerization State of CCR7
(A) Illustration of the directed evolutionary screening to identify surface expressed, oligomer-deficient CCR7 mutants.
(B) Determining the oligomerization state of CCR7mutants and a natural CCR7 SNPmeasured by BiFC and quantified by flow cytometry in transiently transfected
HEK293 cells.
(C) Localization of themutants in the b2-AR-basedCCR7 oligomermodel. Residues involved in CCR7 oligomerization are in red. Designed peptidesmimicking the
oligomer interface for the inhibition study are shown in violet.
(D) Specific migration of 300-19 transfectants expressing CCR7 mutants in 2D Transwell chemotaxis assays toward 0.5 mg/ml CCL19 or CCL21.
(E) Specific Transwell migration of primary T cells treated with designed peptides mimicking the oligomer interface in response to chemokines.
Mean values ± SEM of four (E), six (D), or eight (B) experiments; ANOVA with Tukey post test. See also Figure S3.
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A315G/L325S) was significantly reduced (Figures 4A and 4B).
In contrast, both CCR7 super-oligomerizing mutants (A315V,
V317I SNP) showed significantly augmented Src association
(Figures 4A and 4B). CCR7 also interacted with Src in human
MoDCs matured in the presence of PGE2 (Figure S4B). Src
had to be anchored to the plasma membrane to interact
with CCR7 and required an intact SH3-SH2-linker motif, but
not its kinase activity (Figures S4C–S4E). Moreover, CCR7
triggering induced auto-phosphorylation of Src on Y416
(Figure 4C). Notably, chemokine-mediated SrcY416 phosphory-
lation was strongly enhanced in cells expressing the CCR7
super-oligomerizers but severely impaired in cells expressing
the oligomer-defective CCR7-A315G/L325S mutant (Figure 4C).
CCR7-mediated SrcY416 phosphorylation was also confirmed
in primary human PBLs (Figure S4F).
Structural insights from the b2-AR-G protein complex on the
one hand (Rasmussen et al., 2011) and the b1-AR oligomer on
the other hand (Huang et al., 2013) predict that in an oligomeric
arrangement, a GPCR tetramer allows docking of only two G
proteins, leaving two receptor molecules unoccupied (Huang
et al., 2013). Hence, the question arose whether there could
happen G protein-independent signaling by arranging two
CCR7 dimers as tetramer with one associated trimeric G protein
per dimer. Here, Src theoretically fitted into the free space be-
tween the G proteins (Figure 4D). In this CCR7 tetramer model,
Src would interact not only with the two central receptors, but
also with the G proteins bound to the outer receptors. To test
this scenario, we monitored Src interaction with the G protein.
Indeed, Src interacted not only with the CCR7-mer, but also
with Gai, Gb2, and Gg2 (Figures S4G and S4H), which is in line
with the fact that Src is a direct effector of Gai proteins in recon-
stituted systems (Ma et al., 2000). Astonishingly, at sites of Src-G
protein interaction, numerous peripheral circular ruffles contain-
ing filamentous actin emerged (Figure S4G). Thus, our data
Figure 4. Src Associates with the CCR7 Oligomer and Becomes Activated upon Chemokine Stimulation
(A) Confocal image of the Src-CCR7 interaction visualized by BiFC.
(B) Quantification of Src-CCR7 interaction by BiFC and flow cytometry.
(C) Determining CCR7-mediated Src auto-phosphorylation on Y416 in HEK293 cells expressing CCR7 variants by immunoblotting.
(D) Model of the CCR7-G protein-Src complex.
Mean values ± SD of three (A, C) or six (B) experiments; ANOVA with Tukey post test. See also Figure S4.
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revealed that the interaction of CCR7 with Src depended on the
oligomeric state of the receptor, establishing a new signaling
scaffold to integrate G protein- and Src-dependent pathways.
Phosphorylation of CCR7 by Src Contributes to Efficient
Cell Migration
We found that the interaction of Src with CCR7 depended on re-
ceptor oligomerization and that Src was auto-phosphorylated
upon CCR7 triggering, so we examined whether Src was
able to phosphorylate CCR7. Tyrosine phosphorylation (pTyr)
of CCR7 was found exclusively upon chemokine stimulation
(Figures 5A and S5A). Chemokine-induced CCR7 phosphoryla-
tion was completely abolished in cells pre-treated with the Src
kinase inhibitor PP2, but not by blocking Gai signaling via PTx
(Figure 5B). In line with CCR7 oligomer-dependent Src inter-
action, chemokine-mediated pTyr of CCR7 was reduced in
oligomerization-defective mutants, but enhanced in super-oligo-
merizers, including the CCR7V317I SNP (Figure S5B).Moreover,
robust chemokine-mediated pTyr of CCR7 was found in mature
MoDCs, particularly in those cells exposed to PGE2 (Figure 5C),
corroborating oligomerization-dependent pTyr of CCR7.
Because CCR2 has been shown to be phosphorylated on the
conserved tyrosine of the DRY motif (Mellado et al., 1998), we
mutated the corresponding Y155 of CCR7 to phenylalanine
and found that chemokine-mediated pTyr was hampered (Fig-
ure 5D). Importantly, cells expressing CCR7 Y155F migrated
profoundly less both in 2D and 3D toward CCL19 and CCL21
as compared to cells expressing wild-type CCR7 (Figures 5E
and S5C). Because the DRY motif is essential for G protein
coupling, we next examined whether the Y155F substitution
affected G protein coupling. In contrast to a CCR7 R154N
(DNY) mutant that was unable to activate Gai and did not induce
cell migration (Figures 5E, 5G, S5C, and S5D), we measured
normal G protein activation and calcium mobilization upon che-
mokine binding in our CCR7 Y155F mutant (Figures 5G, S5D,
and S5E). Of note, we demonstrated that not only G protein inhi-
bition but also Src inhibition abrogated CCR7-mediated migra-
tion of primary human T cells (Figure 5F), although G protein
inhibition was more effective. Taken together, we demonstrated
not only that Src tyrosine phosphorylated CCR7, but also that
Src inhibition and mutating the tyrosine residue within the DRY
motif of CCR7 hampered cell migration.
Phosphorylated Y155 of CCR7 Serves as Docking Site
for the Tyrosine Phosphatase SHP2
To further elucidate the new signaling pathway initiated by the
CCR7 oligomer, we performed a screen to identify SH2 domains
recognizing tyrosine-phosphorylated CCR7. Because SH2 do-
mains are known interaction modules recognizing linear motifs
including pTyr residues, we used a panel of purified GST-SH2-
domain fusion proteins for screening (Figures S5F and S5G).
The C-terminal SH2 domain of the tyrosine phosphatase SHP2
most effectively interacted with phosphorylated CCR7 (Fig-
ure S5H). SHP2 harbors two SH2 domains (Figure S5I). In its
inactive conformation, the N-terminal SH2 domain is folded
over the catalytic cleft, preventing interaction with its substrates
(Neel et al., 2003). With its C-terminal SH2 domain, SHP2 sur-
veys the cell for potential interaction partners. Upon binding of
the C-terminal SH2 domain, auto-inhibition is relieved and
SHP2 becomes catalytically active. To become fully activated,
SHP2 needs to be phosphorylated on two tyrosine residues in
its C terminus, resulting in interaction with phosphorylated resi-
dues and SH2 domains in cis. Using co-immunoprecipitation
experiments, we confirmed that SHP2 was specifically recruited
to CCR7 upon chemokine stimulation (Figure 6A). Of note, SHP2
was not recruited to the CCR7 Y155F mutant (Figure S6A).
Because CCR7 phosphorylation was dependent on Src, we
asked whether the interaction of CCR7 with SHP2 occurred in
a G protein-parallel manner. To address this, we exploited a ra-
pamycin-inducible active Src to determine SHP2 recruitment to
CCR7 by BiFC. This approach allowed us to circumvent chemo-
kine stimulation and G protein activation. We found that active
Src was necessary and sufficient to recruit SHP2 to CCR7.
No CCR7-SHP2 interaction was measurable in cells express-
ing either a kinase-dead mutant of Src or phosphorylation-
deficient CCR7 Y155F (Figures 6B and S6B). Thus, we showed
not only that pTyr residue of the DRY motif served as docking
site for SH2-domain-containing proteins, such as SHP2, but
also that Src was necessary and sufficient to induce this
interaction.
Moreover, both CCL19 and CCL21 led to a rapid phosphory-
lation of SHP2 (Figure 6C) but not of SHP1 (Figure S6C) in
primary human PBLs. Chemokine-mediated SHP2 phosphoryla-
tion was dependent on Src as shown by PP2 treatment of PBLs
(Figure S6D). Chemokine-mediated SHP2 phosphorylation was
independent of G protein coupling and could not be blocked
by a JAK inhibitor (Figure S6D). The latter is interesting because
JAK2 is shown to tyrosine phosphorylate CCR2 in a G protein-
parallel but dimerization-dependent manner (Mellado et al.,
1998).
Because SHP2 activity is highly regulated not only through
binding to interaction partners or substrates but also through re-
lief of auto-inhibition and interaction in cis, we aimed to examine
the SHP2 activity after CCR7 stimulation. Therefore, we devel-
oped a phosphatase activity assay with a phospho-peptide as
substrate (Figure S6E). In line with SHP2 phosphorylation,
SHP2 catalytic activity co-immunoprecipitated with CCR7 was
similarly triggered by both CCL19 and CCL21 (Figure S6E).
Despite comparable SHP2 phosphorylation and catalytic activity
at the receptor, CCL21 triggering resulted in several-fold higher
cytosolic activity of SHP2 in T cells than CCL19 (Figure 6D).
Thus, we provide the first evidence for a CCL21-induced biased
signaling pathway through an additional cytosolic pool of SHP2
catalytic activity.
SHP2 Is Critical for Biased Signaling and Migration by
CCL21
Knowing that SHP2 was activated upon CCR7 stimulation and
that SHP2 was not involved in CCR7 de-phosphorylation
(instead, SHP2 inhibition decreased CCR7 phosphorylation)
(Figure 5D), we examined the role of SHP2 in CCR7-driven cell
migration. Therefore, primary human T cells were pre-treated
with the SHP inhibitor NSC-87877 or the SHP2 inhibitor
PHPS1 to block SHP2 catalytic activity but not its adaptor func-
tion. Inhibition of SHP2 did not significantly affect CCL19-medi-
ated T cell migration, whereas T cell migration toward CCL21
was severely impaired in cells treated with NSC-87877 (Fig-
ure 6E) or PHPS1 (Figure 6F). That SHP2 was critical for biased
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Figure 5. Src Tyrosine Phosphorylates CCR7 upon Chemokine Stimulation to Control Migration
(A) HA-taggedCCR7 fromCCL19- andCCL21-stimulated cells was immunoprecipitated (IP) from cell lysates and its tyrosine phosphorylation (pY) determined by
immunoblotting.
(B) Determining CCR7 pTyr in cells treated with the Src inhibitor PP2 or the G protein coupling inhibitor PTx as in (A).
(C) Micrograph of CCR7 pTyr assessed by PLA using anti-CCR7 Ab (SAB4500329) and anti-pTyr mAb (4G10) in (CC ± PGE2) matured MoDCs.
(legend continued on next page)
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CCL21-driven migration was confirmed in human B cells and
MoDCs (Figures 6G and 6H).
In summary, we established that CCR7 oligomerization gener-
ated a novel platform to integrate G protein- and Src-dependent
signaling resulting in tyrosine phosphorylation of CCR7. More-
over, we demonstrated that this CCR7 phosphorylation served
as docking site for SH2-domain-containing signaling proteins.
Finally, we showed CCL21 biased signaling for efficient cell
migration involving a cytosolic pool of catalytically active SHP2.
DISCUSSION
Here we described a previously unknown mechanism of how
environmental cues control immune cell migration bymodulating
the oligomerization state of the chemokine receptor CCR7
enabling integration of distinct signaling pathways at the recep-
tor oligomer interface. We identified that inflammatory signals
and PGE2 provoked oligomerization of CCR7 on DCs. The
same signals led to a profound downregulation of genes involved
in cholesterol biosynthesis and metabolism. Lowering cellular
cholesterol levels by drugs interfered with CCR7 oligomerization
and cell migration, so we propose that this represents a molec-
ular mechanism by which only PGE2-exposed DCs efficiently
emigrate from inflammatory sites to home to draining lymph no-
des (Kabashima et al., 2003; Legler et al., 2006). We showed that
CCR7 oligomerization established a platform to elicit distinct
signaling pathways controlling cell migration. Based on our
oligomeric CCR7 model and experimental evidence, we pro-
posed that within a tetrameric organization, two receptors
couple to Gai proteins to elicit the well-established ‘‘classical’’
chemokine receptor signaling pathway. In addition, this arrange-
ment permitted Src kinase to interact with the uncoupled two
CCR7 molecules of the tetrameric complex. Indeed, we found
that Src interaction with CCR7 depended on the oligomerization
state of the receptor and initiated a G protein parallel signaling
pathway contributing to efficient cell migration.
The signaling hub function of oligomeric receptors is appealing
because previous studies derived from other GPCRs proposed
allosteric modulation of signaling by receptor dimerization (Han
et al., 2009; Huang et al., 2013). The concept of eliciting two
orthogonal and mechanistically separated signaling pathways
is particularly practical at sites of infection because many bacte-
ria produce toxins to target either regulatory GTPases or hetero-
trimeric G proteins of the host to circumvent the host defense
(Aktories, 2011). One of these toxins, PTx, ADP ribosylates Gai
proteins to prevent chemokine-mediated receptor activation
and leukocyte recruitment. Hence, CCR7 oligomerization and
thereby establishing a signaling hub that allows simultaneous
G protein-dependent and Src-dependent signaling pathways al-
lows DCs to integrate distinct signaling pathways to ensure fast
and efficient homing to draining lymph nodes. Interestingly,
effector T cells also expressed CCR7 oligomers and their migra-
tion was less sensitive to PTx, permitting adaptation of signaling
to environmental cues. This notion is in line with a previous study
describing that antigen-experienced effector T cells evolved to
bypass Gai signaling on inflamed vessels in order to access
the injured tissue (Shulman et al., 2012).
Despite their fundamental role in health and disease, pharma-
ceutical targeting of chemokine receptors has been difficult and
of disappointing success. The low success has been attributed
to the redundancy of chemokines acting on the same receptor.
The discovery of biased signaling might be a solution for new at-
tempts in developing new drugs. CCR7 represents a prototype
receptor for biased signaling (Zidar et al., 2009). Whereas equal
receptor-binding affinities and equal G protein activation (Koh-
out et al., 2004) suggests high redundancy in CCR7 signaling,
some signaling characteristics appear to be unique to either
CCL19 or CCL21. Most prominently, only CCL19 (and not
CCL21) promotes CCR7 internalization (Otero et al., 2006).
This CCL19 bias is reported to rely on robust phosphorylation
on Ser/Thr residues in the C terminus of CCR7 by GRK3 and
GRK6, resulting in stronger b-arrestin recruitment and ERK acti-
vation (Kohout et al., 2004; Zidar et al., 2009) and subsequent
CCR7 internalization via clathrin-coated pits (Otero et al.,
2006). CCL19-mediated CCR7 sequestration from the plasma
membrane and its trafficking into clathrin-coated vesicles
might limit its accessibility for downstream signaling molecules.
Therefore, it came of no surprise that CCL19-triggered CCR7
phosphorylation is terminated on a short-term scale, whereas
CCL21-mediated phosphorylation seemed to be more pro-
longed. Up to now, bias-signaling molecules have been
described only for CCL19, not for CCL21. Herein, we showed
that both CCL19 and CCL21 led to the recruitment and the
release of the auto-inhibition of the tyrosine phosphatase
SHP2, whereas only CCL21 triggering established a prominent
pool of cytosolic active SHP2. Surprisingly, the phosphorylation
status of SHP2 was found to be equal in cells stimulated with
either CCL19 or CCL21. Because CCL19-triggered CCR7 is
internalized and traffics via early endosomes to the trans-
Golgi-network (Schaeuble et al., 2012), whereas CCL21-trig-
gered CCR7 remains at the plasma membrane, we proposed
that SHP2 catalytic activity was spatially controlled through the
interaction of a second adaptor molecule in a spatio-temporal
manner. Because CCL21-mediated CCR7 stimulation resulted
in a prominent pool of catalytic active SHP2, it is not surprising
to note that inhibition of SHP2 specifically hampered CCL21-
driven, but not CCL19-driven, DC and lymphocyte migration.
Overall, our finding that the oligomerization state of CCR7
shapes cell migration together with the possibility to modulate
CCR7 oligomerization by changing cholesterol levels, by
using oligomer-intercalating peptides or by specifically inhib-
iting CCL21, but not CCL19-mediated migration, sets the
(D) Micrograph of a 3D reconstruction showing CCL19-mediated CCR7 pTyr by PLA in HEK293 cells expressing HA-tagged wild-type or Y155F CCR7 pretreated
or not with 10 mM PP2 and 40 mM NSC87877.
(E) Specific Transwell cell migration toward CCL19 and CCL21 of 300-19 cells expressing a phosphorylation-defective (CCR7 Y155F) and a G protein-coupling-
deficient mutant (CCR7 DNY).
(F) Specific CCR7-dependent Transwell migration of primary human T cell migration pre-treated for 2 hr with 10 mM PP2 or 100 ng/ml PTx.
(G) CCL19-mediated calcium mobilization in 300-19 transfectants expressing CCR7 mutants.
Data represent at least three experiments (A–D, G). Mean ± SEM of six (E) or four (F) experiments; ANOVA with Tukey post test. See also Figure S5.
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groundwork for biomedical implications. New ways of reducing
CCR7-driven migration is desirable in the case of chronic inflam-
matory diseases or to prevent metastasis formation, whereas
enhancing CCR7-driven migration would be highly appreciated
in attempts to boost the immune system in a vaccine response.
EXPERIMENTAL PROCEDURES
Migration Assays
Cell migration in 2D was assessed with the Transwell systems with polycar-
bonate filters (Corning Costar). 3D migration was performed in bovine Purecol
collagenI (3mg/ml; AdvancedBiomatrix). More details are provided in the Sup-
plemental Experimental Procedures.
Proximity Ligation Assay
CCR7-CCR7 interaction was examined with reagents from the Duolink PLA
(Sigma-Aldrich). In brief, for cholesterol depletion, cells were pre-incubated for
48 hr with 10 mM Mevastatin or 10 mM Pravastatin and for 2 hr with 0.6 M
MbCD or 25 U/ml cholesterol oxidase. For visualization of pTyr CCR7, cells
attached to cover slides were stimulated with 0.5 mg/ml CCL19/CCL21. Cells
or snap-frozen skin sections were fixed, blocked, and stained with primary anti-
body and secondary antibodies harboring short nucleotide sequences.
Oligonucleotideswere ligatedat 37C,and rollingcirclePCRwithfluorescent nu-
cleotides was performed for 2 hr. PLA was visualized with an inverted confocal
microscope. For further details see Supplemental Experimental Procedures.
Quantitative Real-Time PCR
Total RNA of MoDCs was isolated and transcribed into cDNA. Amplification of
transcripts was performed with the Lipoprotein Signaling and Cholesterol
Metabolism RT2 Profiler PCR Array (QIAGEN) on a 7900HT Fast Real-Time
PCR System (Applied Biosystems).
FRET Measurements
Intermolecular FRETefficiencywasmeasured inHEK293 cells stably expressing
CCR7-EYFP transiently transfectedwith either TMEM16a-ECFPorCCR7-ECFP
and fixed. A pre-bleaching imagewas taken, and then the acceptor of the whole
cell was bleached at 100% laser intensity and FRET efficiency was calculated.
Further details are provided in the Supplemental Experimental Procedures.
BiFC Assay
HEK293 were co-transfected with splitYFP1 and splitYFP2-tagged constructs
and stimulatedwith 0.5 mg/ml CCL19 or CCL21. Fixed cells were detached and
analyzed by flow cytometry. For immunofluorescence microscopy, cells were
permeabilized and stained. Images were acquired by confocal microscopy.
For further details see Supplemental Experimental Procedures.
Cys-Mediated Cross-linking
HEK293 cells transfected with HA-tagged CCR7 were either pre-treated with
MbCD or not and reacted for 10 min at RT with 400 mM copper sulfate and
1,10-phenanthroline. Proteins were separated by SDS-PAGE and detected
by immunoblotting using an anti-HA peroxidase antibody. Detailed information
provided in Supplemental Experimental Procedures.
Co-immunoprecipitation
HEK293 expressing CCR7-HA or mutants thereof were starved, stimulated
with chemokine, and subsequently incubated with 2.5 mM dithio-bis-succini-
midyl propionate. Cells were lysed and HA-tagged CCR7was immuno-precip-
itated with anti-HA-agarose. Immunoprecipitated proteins were analyzed by
immunoblotting. Detailed information provided in the Supplemental Experi-
mental Procedures.
Statistical Evaluation
Significant differences between groups were assessedwith ANOVAwith either
Tukey or Dunnett post-test using GraphPad Prism v.6. *p < 0.05, ** p < 0.01,
***p < 0.001.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and Supplemental Experimental
Procedures and can be found with this article online at http://dx.doi.org/10.
1016/j.immuni.2015.12.010.
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